Breaking Finance News

A statement released earlier today by Mizuho Securities about Dermira (NASDAQ:DERM) bumps down the target price to $40.00

Having a price of $27.52, Dermira (NASDAQ:DERM) traded -1.20% lower on the day. With the last close down -10.79% from the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the same period. Dermira has recorded a 50-day average of $24.54 and a two hundred day average of $29.41. Volume of trade was down over the average, with 338,894 shares of DERM changing hands under the typical 418,186

Stating a potential upside of 0.45%, Mizuho Securities dropped the price target of Dermira (NASDAQ:DERM) to $40.00

On Friday March 31, 2017, Mizuho Securities released a statement on Dermira (NASDAQ:DERM) upped the target price from $0.00 to $42.00 that suggested an upside of 0.21%.

Performance Chart

Dermira (NASDAQ:DERM)

With a total market value of $0, Dermira has with a one year low of $21.35 and a one year high of $38.75 .

A total of 5 analysts have released a research note on Dermira. zero analysts rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $42.60.

More About Dermira (NASDAQ:DERM)

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *